IDH1 and glioma: Another interesting finding is that 5-mC% levels were significantly lower in high-grade tumors and glioblastoma and marginally lower in IDH1 mutation–negative tumors than in low-grade tumors, non-glioblastoma gliomas, and IDH1 mutation–positive tumors.